A Systematic Review Evaluating the Efficacy of Intra-Ovarian Infusion of Autologous Platelet-Rich Plasma in Patients With Poor Ovarian Reserve or Ovarian Insufficiency

Soumya R Panda, Shikha Sachan, Smrutismita Hota, Soumya R Panda, Shikha Sachan, Smrutismita Hota

Abstract

The emergence of autologous platelet-rich plasma (PRP) therapy reflects a break-through for infertile patients with premature ovarian failure. To study the efficacy of intra-ovarian infusion of autologous PRP on the improvement of ovarian reserve parameters and the subsequent artificial reproductive technique (ART) cycle outcomes in infertile women with poor ovarian reserve or premature ovarian insufficiency, a systematic search in electronic databases like Medline (through PubMed), Embase, Scopus, Web of Science, and Cochrane was done using relevant search terms. Except for case series, case reports, and review articles, all other types of studies, those evaluated for the effects of intra-ovarian infusion of PRP in subfertile women for decreased ovarian reserve (DOR) or premature ovarian insufficiency (POI) were included in our systematic review. The data were extracted from each eligible study and cross-checked by two authors. Intra-ovarian PRP infusion appears to be effective in ovarian rejuvenation, and the results of the subsequent intracytoplasmic sperm injection (ICSI) cycle are encouraging. PRP intervention was found to be beneficial in terms of an improvement in ovarian reserve parameters (increase in serum anti-mullerian hormone or antral follicle count or decrease in serum follicular stimulating hormone). ICSI cycle performance in terms of the total number of oocytes retrieved, number of two-pronuclei embryos, fertilization rate, number of cleavage stage embryos, number of good quality embryos, and cycle cancellation rate were found to be improved after intra-ovarian PRP infusion as compared to their previous cycle without PRP infusion.

Keywords: decreased ovarian reserve; platelet-rich plasma; premature menopause; premature ovarian insufficiency; prp.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020, Panda et al.

Figures

Figure 1. Flow of information through the…
Figure 1. Flow of information through the different phases of the systematic review (according to PRISMA)
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

References

    1. Ovarian aging. Seli E. Semin Reprod Med. 2015;33:375–376.
    1. Female age-related fertility decline. Committee opinion no. 589. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Fertil Steril. 2014;101:633–634.
    1. Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women. Battaglia DE, Goodwin P, Klein NA, Soules MR. Hum Reprod. 1996;11:2217–2222.
    1. The impact of lifestyle modifications, diet, and vitamin supplementation on natural fertility. Collins GG, Rossi BV. . Fertil Res Pract. 2015;1:11.
    1. Level of vitamin E in follicular fluid and serum and oocyte morphology and embryo quality in patients undergoing IVF treatment. Bahadori MH, Sharami SH, Fakor F, Milani F, Pourmarzi D, Dalil-Heirati SF. J Family Reprod Health. 2017;11:74–81.
    1. The role of melatonin as an antioxidant in the follicle. Tamura H, Takasaki A, Taketani T, et al. J Ovarian Res. 2012;5:5.
    1. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gat I, Blanco Mejia S, Balakier H, Librach CL, Claessens A, Ryan EA. Gynecol Endocrinol. 2016;32:534–537.
    1. Can coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage? Özcan P, Fıçıcıoğlu C, Kizilkale O, Yesiladali M, Tok OE, Ozkan F, Esrefoglu M. J Assist Reprod Genet. 2016;33:1223–1230.
    1. Oxidative stress and antioxidants: exposure and impact on female fertility. Ruder EH, Hartman TJ, Blumberg J, Goldman MB. Hum Reprod Update. 2008;14:345–357.
    1. Antioxidants for female subfertility. Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ. Cochrane Database Syst Rev. 2017;7:0.
    1. Menopause symptom management in the United Kingdom. Holloway D. Nurs Clin North Am. 2018;53:263–277.
    1. Prise en charge en Assistance médicale à la procréation des femmes de 38 ans et plus: résultats d'une enquête à propos de 84 couples. Assisted reproductive techniques in women aged 38 years or more [Article in French] Lamarche C, Lévy R, Felloni B, et al. Gynecol Obstet Fertil. 2007;35:420–429.
    1. Oocyte donation in low responders to conventional ovarian stimulation for in vitro fertilization. Remohi J, Vidal A, Pellicer A. Fertil Steril. 1993;59:1208–1215.
    1. Pregnancy after age 50: application of oocyte donation to women after natural menopause. Sauer MV, Paulson RJ, Lobo RA. Lancet. 1993;6:321–323.
    1. Ovarian transplantation between monozygotic twins discordant for premature ovarian failure. Silber SJ, Lenahan KM, Levine DJ, et al. N Engl J Med. 2005;353:58–63.
    1. A new approach to primary ovarian insufficiency. Rafique S, Sterling EW, Nelson LM. Obstet Gynecol Clin North Am. 2012;39:567–586.
    1. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Corrêa do Amaral RJ, Granjeiro JM, Borojevic R. Stem Cell Res Ther. 2013;7:67.
    1. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Sterne JA, Hernán MA, Reeves BC, et al. BMJ. 2016;12:4919.
    1. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Cakiroglu Y, Saltik A, Yuceturk A, et al. Aging. 2020;12:10211.
    1. The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. Melo P, Navarro C, Jones C, Coward K, Coleman L. J Assist Reprod Genet. 2020;37:855–863.
    1. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women. Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. J Clin Med. 2020;9:1809.
    1. Regenerative effect of intraovarian injection of activated autologous platelet rich plasma: serum anti-mullerian hormone levels measured among poor-prognosis in vitro fertilization patients. Sills E, Sills E, Petersen J, Rickers N, Wood S, Li X. International Journal of Regenerative Medicine. 2020;1:5.
    1. Rapid healing and reduced erythema after ablative fractional carbon dioxide laser resurfacing combined with the application of autologous platelet-rich plasma. Na JI, Choi JW, Choi HR, Jeong JB, Park KC, Youn SW, Huh CH. Dermatol Surg. 2011;37:463–468.
    1. Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: Upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells. Park HB, Yang JH, Chung KH. Korean J Hematol. 2011;46:265–273.
    1. Platelet-rich plasma peptides: key for regeneration. Sánchez-González DJ, Méndez-Bolaina E, Trejo-Bahena NI. Int J Pept. 2012;2012:532519.
    1. Stem-cell therapy and platelet-rich plasma in regenerative medicines: a review on pros and cons of the technologies. Ramaswamy Reddy SH, Reddy R, Babu NC, Ashok GN. J Oral Maxillofac Pathol. 2018;3:367–374.
    1. Platelet-rich plasma in muscle healing. Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F. Am J Phys Med Rehabil. 2010;89:854–861.
    1. Blood coagulation; evidence of an antagonist to factor VI in platelet-rich human plasma. Kingsley CS. Nature. 1954;17:723–724.
    1. Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. Fanciulli G, Delitala A, Delitala G. Hum Reprod Update. 2009;15:341–358.
    1. Current clinical applications of platelet-rich plasma in various gynecological disorders: an appraisal of theory and practice. Dawood AS, Salem HA. Clin Exp Reprod Med. 2018;45:67–74.
    1. Protective effect of platelet rich plasma on experimental ischemia/reperfusion injury in rat ovary. Bakacak M, Bostanci MS, İnanc F, et al. Gynecol Obstet Invest. 2016;81:225–231.
    1. A case series on platelet-rich plasma revolutionary management of poor responder patients. Sfakianoudis K, Simopoulou M, Nitsos N, et al. Gynecol Obstet Invest. 2018;84:99–106.
    1. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Int J Clin Exp Med. 2015;8:1286–1290.
    1. Effects of autologous platelet-rich plasma on implantation and pregnancy in repeated implantation failure: a pilot study. Nazari L, Salehpour S, Hoseini S, Zadehmodarres S, Ajori L. Int J Reprod Biomed. 2016;14:625–628.
    1. Autologous platelet-rich plasma treatment enables pregnancy for a woman in premature menopause. Sfakianoudis K, Simopoulou M, Nitsos N, et al. J Clin Med. 2019;8:1.
    1. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Hosseini L, Shirazi A, Naderi MM, et al. Reprod Biomed Online. 2017;35:343–350.
    1. A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following platelet-rich plasma treatment. Pantos K, Simopoulou M, Pantou A, et al. Cell Transplant. 2019;28:1333–1340.
    1. First data on vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Sills E, Rickers N, Li X, Palermo G. Gynecol Endocrinol. 2018;34:756–760.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel